

web: <http://covidcirrhosis.org>
email: covid.cirrhosis@unc.edu
twitter: @SecureCirrhosis


web: <https://covid-hep.net>
email: info@covid-hep.net
twitter: @COVIDHep

Combined weekly update – 05 Apr 2020

We continue to wish everyone working to fight COVID-19 well and we welcome you to this combined update from our two collaborating international registries: **SECURE-Cirrhosis** covering North and South America, China/Japan/Korea and **COVID-Hep with EASL** covering the rest of the world in an attempt to collate clinical details of patients with chronic liver disease who develop COVID-19.

Total cohort (n = 419)


Submissions over time



Characteristics

386 (93%) hospitalised
269 (64.2%) men
Median age 59 years (IQR 47-68)

Submissions from 25 countries



Chronic liver disease, non-cirrhotic (n = 176)

Major outcomes

Intensive care admission	32	18%
Invasive ventilation	30	17%
Death	10	6%

Cirrhosis (n = 185)

Major aetiologies

Alcohol	55	30%
Non-alcoholic steatohepatitis	32	17%
Hepatitis C	20	11%
Hepatitis B	17	9%
Haemochromatosis	15	8%
Autoimmune hepatitis	9	5%
Alcohol & HCV	9	5%
Others and mixed	28	15%

Decompensation

Any	71	38%
New or worse ascites	42	23%
New or worse encephalopathy	40	22%
Variceal bleeding	5	3%

Major outcomes

Intensive care admission	45	24%
Invasive ventilation	28	15%
Death	68	37%

Liver transplant (n = 58)

Major outcomes

Intensive care admission	13	22%
Invasive ventilation	12	21%
Death	13	22%